All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The pleasant memories of summer vacations are sure to fade quickly for biotech investors who are returning, post-Labor Day, to the harsh realities of markets that are not ready to embrace the sector anytime soon. As we head to the end of the third quarter, there is no momentum being built by blue-chip biopharmaceutical companies, as their share values languished once again last month.